The specific aim of this grant is to mentor young clinical investigators, primarily in the area of research related to the control of symptoms caused by cancer and/or cancer therapy. A time comes in an investigator's career when a previously mentored person becomes the mentor. Although it might not be easy to admit, being more than half way through my career, I have made the transformation from primarily being mentored, to being a mentor. I am currently the Director of the Cancer Control Program of the North Central Cancer Treatment Group (NCCTG) as well as the co-director of the Cancer Prevention and Control Program of the Mayo Clinic Comprehensive Cancer Center. I have been the Principal Investigator of a community clinical oncology program (CCOP) research base grant for over a decade and have received R01 grant funding in the past. The last two competitive renewals of the CCOP research base grant that I submitted both received an identical outstanding score, that being 123. Through this effort, I have, arguably, developed the most productive program in the world designed to evaluate means of alleviating symptoms caused by cancer and/or cancer therapy. Using this background, with the funds obtained from this grant I will provide mentorship for young clinical investigators interested in a career in clinical research related to relief of symptoms from cancer and/or cancer therapy. I will use an "on-the-job" training approach to help them with the development of applicable protocols. I will mentor them through the protocol review process, through the conduct of the clinical trial, and through the process to report results as a manuscript. I will facilitate their leadership of subsections of the Mayo Oncology Symptom Control Program. I will facilitate their development of independent grant funding. I view this as a process of succession planning, expecting that one or more of these mentored individuals will eventually take my place and continue to promulgate the symptom control research program that we have here, allowing them to mentor the next generation of investigators. This role as a mentor allows me to give back to the scientific field some of the fruits from the mentoring that was provided to me in my early career. This should allow for continued investigation for promising means for alleviating symptoms related to cancer and/or cancer therapy. This will allow for improved care of patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Scientist Award (K05)
Project #
5K05CA124477-05
Application #
8282597
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
2008-06-01
Project End
2013-12-31
Budget Start
2012-06-01
Budget End
2013-12-31
Support Year
5
Fiscal Year
2012
Total Cost
$156,128
Indirect Cost
$11,565
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74
Pachman, Deirdre R; Weisbrod, Breanna L; Seisler, Drew K et al. (2015) Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer 23:943-51
Kadakia, Kunal C; Leal, Alexis D; Seisler, Drew K et al. (2014) Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer 22:217-23
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Kadakia, Kunal C; Rozell, Shaina A; Butala, Anish A et al. (2014) Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage 47:1100-15
Leal, A D; Kadakia, K C; Looker, S et al. (2014) Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 22:1313-7
Staff, Nathan P; Podratz, Jewel L; Grassner, Lukas et al. (2013) Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 39:124-31
Stan, Daniela; Loprinzi, Charles L; Ruddy, Kathryn J (2013) Breast cancer survivorship issues. Hematol Oncol Clin North Am 27:805-27, ix
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 45 publications